{"id":{"repo_id":"birmingham","oai_identifier":"oai:etheses.bham.ac.uk:15296"},"canonical_url":"https://search.ndltd.org/etd/birmingham/oai:etheses.bham.ac.uk:15296","repository":{"repo_id":"birmingham","name":"University of Birmingham","base_url":"https://etheses.bham.ac.uk/cgi/oai2"},"display":{"title":"Investigating the potential of a metabolomic biomarker for pancreatic exocrine insufficiency","abstract":"Pancreatic exocrine insufficiency (PEI) is a reduction in pancreatic enzymes to a level below that required to maintain normal digestion. It is a consequence of many diseases, leading to malnutrition, impaired of quality of life and poor clinical outcomes. Diagnosis of PEI is challenging. This thesis investigates the potential for a novel diagnostic measure of PEI using metabolomics as a discovery tool. The use of metabolomics, the study of the small products of metabolism, in developing novel biomarkers is a rapidly expanding field. This body of work is based on the hypothesis that: A fatty test meal will create a dynamic, measurable response in the food metabolome and that response will be different in those with PEI compared to healthy controls. To test this hypothesis, a trial called DETECTION was designed to obtain fed and fasted plasma samples from patients with PEI alongside healthy controls and use untargeted metabolomics to explore differences in their metabolomic response to a test meal. To accurately determine PEI status, the \\(^{13}\\)Carbon mixed triglyceride breath test (\\(^{13}\\)C MTGT) has been used alongside other markers of PEI. Much of this work has been directed towards developing and refining the \\(^{13}\\)C MTGT for use alongside blood metabolite analysis. In summary, I have created an evidence-based protocol and novel test meal for the \\(^{13}\\)C MTGT that is compatible with post-prandial metabolite analysis. With the results of the DETECTION trial PEI screen, I have evaluated the prevalence of PEI in various patient groups and explored concordance between existing diagnostic tests for PEI. Finally, I have compared the postprandial metabolome of those with and without PEI and found significant differences that have the potential to be used as a biomarker for PEI, this is novel, ground-breaking and has the potential to greatly improve diagnosis and treatment of PEI.","abstract_html":"Pancreatic exocrine insufficiency (PEI) is a reduction in pancreatic enzymes to a level below that required to maintain normal digestion. It is a consequence of many diseases, leading to malnutrition, impaired of quality of life and poor clinical outcomes. Diagnosis of PEI is challenging. This thesis investigates the potential for a novel diagnostic measure of PEI using metabolomics as a discovery tool. The use of metabolomics, the study of the small products of metabolism, in developing novel biomarkers is a rapidly expanding field. This body of work is based on the hypothesis that: A fatty test meal will create a dynamic, measurable response in the food metabolome and that response will be different in those with PEI compared to healthy controls. To test this hypothesis, a trial called DETECTION was designed to obtain fed and fasted plasma samples from patients with PEI alongside healthy controls and use untargeted metabolomics to explore differences in their metabolomic response to a test meal. To accurately determine PEI status, the <span class=\"etd-inline-math\"><sup>13</sup></span>Carbon mixed triglyceride breath test (<span class=\"etd-inline-math\"><sup>13</sup></span>C MTGT) has been used alongside other markers of PEI. Much of this work has been directed towards developing and refining the <span class=\"etd-inline-math\"><sup>13</sup></span>C MTGT for use alongside blood metabolite analysis. In summary, I have created an evidence-based protocol and novel test meal for the <span class=\"etd-inline-math\"><sup>13</sup></span>C MTGT that is compatible with post-prandial metabolite analysis. With the results of the DETECTION trial PEI screen, I have evaluated the prevalence of PEI in various patient groups and explored concordance between existing diagnostic tests for PEI. Finally, I have compared the postprandial metabolome of those with and without PEI and found significant differences that have the potential to be used as a biomarker for PEI, this is novel, ground-breaking and has the potential to greatly improve diagnosis and treatment of PEI.","abstract_has_math":true,"creators":["Powell-Brett, Sarah"],"institution":"University of Birmingham","degree_name":"d_ph","degree_level":"d_ph","degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2024,"date_issued":"2024-12","date_published":"2024-12","updated_at":"2026-11-19T09:32:52Z","subjects":["R Medicine (General)","RC Internal medicine"],"languages":["eng"],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":null,"outbound_label":null,"outbound_source":null,"record_url":null,"record_label":null,"record_kind":null,"record_source":null,"download_url":"http://etheses.bham.ac.uk//id/eprint/15296/1/Powell-Brett2024PhD.pdf","download_label":"Download PDF","download_source":"dc:identifier.uri","access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://etheses.bham.ac.uk/cgi/oai2?verb=GetRecord&metadataPrefix=uketd_dc&identifier=oai%3Aetheses.bham.ac.uk%3A15296","prefix":"uketd_dc"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.sponsor","label":"Sponsor","values":["other","wellcome_trust"]},{"key":"dc:creator","label":"Author","values":["Powell-Brett, Sarah"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2024-12-09"]},{"key":"dc:date.issued","label":"Date","values":["2024-12"]},{"key":"dc:publisher.department","label":"Dc Publisher Department","values":["College of Medical & Dental Sciences","Institute of Immunology and Immunotherapy"]},{"key":"dc:publisher.institution","label":"Dc Publisher Institution","values":["University of Birmingham"]},{"key":"dc:relation.isreferencedby","label":"Dc Relation Isreferencedby","values":["http://etheses.bham.ac.uk//id/eprint/15296/"]},{"key":"dc:type","label":"Dc Type","values":["Thesis"]},{"key":"dc:type.qualificationlevel","label":"Dc Type Qualificationlevel","values":["d_ph"]},{"key":"dc:type.qualificationname","label":"Dc Type Qualificationname","values":["d_ph"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["R Medicine (General)","RC Internal medicine"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.dcterms_iso639_2","label":"Language (ISO 639-2)","values":["eng"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["http://etheses.bham.ac.uk//id/eprint/15296/1/Powell-Brett2024PhD.pdf"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Pancreatic exocrine insufficiency (PEI) is a reduction in pancreatic enzymes to a level below that required to maintain normal digestion. It is a consequence of many diseases, leading to malnutrition, impaired of quality of life and poor clinical outcomes. Diagnosis of PEI is challenging. This thesis investigates the potential for a novel diagnostic measure of PEI using metabolomics as a discovery tool. The use of metabolomics, the study of the small products of metabolism, in developing novel biomarkers is a rapidly expanding field. This body of work is based on the hypothesis that: A fatty test meal will create a dynamic, measurable response in the food metabolome and that response will be different in those with PEI compared to healthy controls. To test this hypothesis, a trial called DETECTION was designed to obtain fed and fasted plasma samples from patients with PEI alongside healthy controls and use untargeted metabolomics to explore differences in their metabolomic response to a test meal. To accurately determine PEI status, the \\(^{13}\\)Carbon mixed triglyceride breath test (\\(^{13}\\)C MTGT) has been used alongside other markers of PEI. Much of this work has been directed towards developing and refining the \\(^{13}\\)C MTGT for use alongside blood metabolite analysis. In summary, I have created an evidence-based protocol and novel test meal for the \\(^{13}\\)C MTGT that is compatible with post-prandial metabolite analysis. With the results of the DETECTION trial PEI screen, I have evaluated the prevalence of PEI in various patient groups and explored concordance between existing diagnostic tests for PEI. Finally, I have compared the postprandial metabolome of those with and without PEI and found significant differences that have the potential to be used as a biomarker for PEI, this is novel, ground-breaking and has the potential to greatly improve diagnosis and treatment of PEI."]},{"key":"dc:format","label":"Dc Format","values":["text"]},{"key":"dcterms:accessrights","label":"Dcterms Accessrights","values":["public"]},{"key":"dc:title","label":"Title","values":["Investigating the potential of a metabolomic biomarker for pancreatic exocrine insufficiency"]}]}],"canonical_facts":{"dc:contributor.sponsor":["other","wellcome_trust"],"dc:creator":["Powell-Brett, Sarah"],"dc:date":["2024-12-09"],"dc:date.issued":["2024-12"],"dc:description.abstract":["Pancreatic exocrine insufficiency (PEI) is a reduction in pancreatic enzymes to a level below that required to maintain normal digestion. It is a consequence of many diseases, leading to malnutrition, impaired of quality of life and poor clinical outcomes. Diagnosis of PEI is challenging. This thesis investigates the potential for a novel diagnostic measure of PEI using metabolomics as a discovery tool. The use of metabolomics, the study of the small products of metabolism, in developing novel biomarkers is a rapidly expanding field. This body of work is based on the hypothesis that: A fatty test meal will create a dynamic, measurable response in the food metabolome and that response will be different in those with PEI compared to healthy controls. To test this hypothesis, a trial called DETECTION was designed to obtain fed and fasted plasma samples from patients with PEI alongside healthy controls and use untargeted metabolomics to explore differences in their metabolomic response to a test meal. To accurately determine PEI status, the \\(^{13}\\)Carbon mixed triglyceride breath test (\\(^{13}\\)C MTGT) has been used alongside other markers of PEI. Much of this work has been directed towards developing and refining the \\(^{13}\\)C MTGT for use alongside blood metabolite analysis. In summary, I have created an evidence-based protocol and novel test meal for the \\(^{13}\\)C MTGT that is compatible with post-prandial metabolite analysis. With the results of the DETECTION trial PEI screen, I have evaluated the prevalence of PEI in various patient groups and explored concordance between existing diagnostic tests for PEI. Finally, I have compared the postprandial metabolome of those with and without PEI and found significant differences that have the potential to be used as a biomarker for PEI, this is novel, ground-breaking and has the potential to greatly improve diagnosis and treatment of PEI."],"dc:format":["text"],"dc:identifier.uri":["http://etheses.bham.ac.uk//id/eprint/15296/1/Powell-Brett2024PhD.pdf"],"dc:language.dcterms_iso639_2":["eng"],"dc:publisher.department":["College of Medical & Dental Sciences","Institute of Immunology and Immunotherapy"],"dc:publisher.institution":["University of Birmingham"],"dc:relation.isreferencedby":["http://etheses.bham.ac.uk//id/eprint/15296/"],"dc:subject":["R Medicine (General)","RC Internal medicine"],"dcterms:accessrights":["public"],"dc:title":["Investigating the potential of a metabolomic biomarker for pancreatic exocrine insufficiency"],"dc:type":["Thesis"],"dc:type.qualificationlevel":["d_ph"],"dc:type.qualificationname":["d_ph"]},"updated_at":"2026-11-19T09:32:52Z"}